Q-omics provides the consensus-scored MIR1827 profile across patient tissues and cancer cell-line models. MIR1827 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR1827 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, MIR1827 RNA expression shows 5,699 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where MIR1827 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1827 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1827 survival associations across molecular data types. MIR1827 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1827 RNA expression–survival associations across cancer types. High MIR1827 expression shows unfavorable associations in MESO, BLCA, ACC and GBM, but favorable associations in STAD and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR1827 RNA expression.
This table summarizes MIR1827 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1827. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1827 shows higher tumor expression in LUAD. The LUAD box plot shows higher MIR1827 RNA expression in tumor versus normal tissue (log2 FC = +0.309, t-test p = .020).
This table shows molecular features associated with MIR1827 in patient tissues and cancer cell lines. In patient samples, MIR1827 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
